Prior to joining Medtronic, Weinstein served as a managing director for JP Morgan’s equity research healthcare team, holding positions within the unit for more than 20 years, the Fridley, Minn.-based company said.
“We are excited to welcome Mike to Medtronic. He is deeply respected within the industry and brings with him vast knowledge of our markets, technologies, and growth strategies. I look forward to his contributions to the company, including his expert guidance and insights, as well as the new perspective he will bring to our organization,” Medtronic CEO Omar Ishrak said in a press release.
“Mike brings unique and deep insights of the medical device and technology space to Medtronic, developed during a distinguished career in equity research at J.P. Morgan. He will serve as an integral advisor and partner to our senior leaders, and we are thrilled to welcome him to the team,” Medtronic CFO Karen Parkhill said in a prepared statement.
Weinstein joined JP Morgan in 1992, and moved to become the senior medical technology analyst in 1996, Medtronic said. He will assume his position at Medtronic immediately.
“I see in Medtronic the opportunity to continue to create significant shareholder value, and I couldn’t be more excited to join the global leader in medical technology and contribute to its Mission. Having covered Medtronic for more than two decades now, I have full confidence in the outlook and the strategy, and our ability to unlock that value in the months and years ahead,” Weinstein said in a prepared release.
Onopchenko served as COO since last October, the Irvine, Calif.-based company said. Prior to joining Endologix, Onopchenko acted as exec VP for Acutus Medical, and has held positions including COO at Volcano.
Onopchenko also spent 10 years at Johnson & Johnson (NYSE:JNJ) leading medical device investments with J&J’s Development Corporation, and held positions with General Electric (NYSE:GE) Medical, Endologix said.
“We are very pleased to welcome John as our chief executive officer. Over the course of the past seven months in the COO role, John has shown the board first hand that he is an exceptional operator with significant manufacturing, clinical, and regulatory experience. His proven skills in scaling and improving productivity in global commercial organizations at Johnson & Johnson and GE Medical and as a medical device venture capitalist give us confidence in his ability to lead Endologix on an exciting path forward. Separately, on behalf of the board of directors, I would like to thank John McDermott for his invaluable contributions to Endologix and for making this transition as smooth as possible,” board chair Dan Lemaitre said in a prepared statement.
“I am honored to be named chief executive officer of Endologix. Since joining the company as COO, I have been deeply involved in the operations of the organization, and I’m excited about the bright future that Endologix has ahead of it. I am looking forward to further advancing the company’s innovative portfolio, enhancing its credibility and reputation with our physicians and customers, and building a culture of accountability, with the ultimate goal of delivering value to our stakeholders around the globe,” Onopchenko said in a press release.
“Brad has distinguished himself throughout his entire career, and he has been one of the architects of the remarkable growth that Henry Schein Medical has enjoyed in recent years. Brad’s new appointment reflects his excellence as a senior leader and his ability to drive continued growth,” board chair & CEO Stanley Bergman said in a press release.
Connett joined Henry Schein in 1997 after the company acquired Roane-Barker, the company said.
“Throughout the years, Henry Schein Medical has partnered with health care organizations to drive the development and execution of non-acute supply chain strategies. Brad’s strategic vision, deep-rooted industry knowledge, and wide network will advance our ability to deliver innovative solutions that helps our medical professionals operate efficient and profitable practices,” CCO David McKinley said in a prepared statement.
The company said it will engage in a search for a new dental segment leader, and during the transition the dental biz will report to Mark Walchirk.
“We are grateful to Dave for his many contributions to Patterson during his 22 years with our dental business, and I thank him for his support during my transition. On behalf of Patterson, we wish him the best in his future endeavors,” prez & CEO Mark Walchirk said in a prepared release.
During his time at Alere, Hinrichs initiated a performance improvement program looking to save over $150 million through integration, standardization and scale-building projects, according to a Cibus release. He also held a CFO position with CareFusion, Cibus said.
“Jim’s leadership will take Cibus to the next level as we execute sales for our robust pipeline of food and agricultural products. His impressive experience in the healthcare and biotech industries offers a well-rounded perspective and will bolster Cibus’ expanding presence in the agriculture industry,” Cibus prez & CEO Peter Beetham said in a press release.